Anatara Lifesciences : Change of Director's Interest Notice

About this update from Anatara Lifesciences Ltd

For personal use only Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Anatara Lifesciences Limited ABN 41 145 239 872 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director David Brookes Date of last notice 4 December 2020 Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Direct or indirect interest Direct & Indirect Nature of indirect interest Indirect - David & Elisabeth Brookes atf Dr (including registered holder) DL Brookes Personal Superfund Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 9 December 2021 No. of securities held prior to change Indirect - David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 300,000 Ordinary Shares & 65,658 Options with an exercise price of $0.2476 and expire on 3 December 2022 Class Options Number acquired Direct: 900,000 at $0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025 Number disposed Nil Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 For personal use only Appendix 3Y Change of Director's Interest Notice No. of securities held after change Direct: 900,000 at $0.225 ea; vesting 450,000 16 November 2022 & 450,000 16 November 2023; expire 14 November 2025 Indirect - David & Elisabeth Brookes atf Dr DL Brookes Personal Superfund 300,000 Ordinary Shares & 65,658 Options with an exercise price of $0.2476 and expire on 3 December 2022 Nature of change Example: on-market trade, off-market trade, exercise of options, The issued Options were approved by issue of securities under dividend reinvestment plan, participation in Shareholders at the Annual General Meeting buy-back held on 16 November 2021 Part 2 - Change of director's interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Detail of contract Nil Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - + Closed period Were the interests in the securities or contracts detailed N/A above traded during a + closed period where prior written clearance was required? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 For personal use only Appendix 3Y Change of Director's Interest Notice If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 For personal use only Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Anatara Lifesciences Limited ABN 41 145 239 872 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Sue MacLeman Date of last notice 13 September 2021 Part 1 - Change of director's relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest N/A (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 9 December 2021 No. of securities held prior to change Indirect - Dalroar Pty Ltd (MacLeman Investment Trust) 78,069 Ordinary Shares & 122,548 Options with an exercise price of $0.2476 and expire on 3 December 2022 Class Options Number acquired Indirect - Dalroar Pty Ltd (MacLeman Investment Trust) 450,000 Options at $0.225 ea; vesting 225,000 16 November 2022 & 225,000 16 November 2023; expire 14 November 2025 Number disposed Nil Value/Consideration Nil Note: If consideration is non-cash, provide details and estimated valuation See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 For personal use only Appendix 3Y Change of Director's Interest Notice No. of securities held after change Indirect - Dalroar Pty Ltd (MacLeman Investment Trust) 78,069 Ordinary Shares; 122,548 Options with an exercise price of $0.2476 and expire on 3 December 2022 & 450,000 Options at $0.225 ea; vesting 225,000 16 November 2022 & 225,000 16 November 2023; expire 14 November 2025 Nature of change Example: on-market trade, off-market trade, exercise of options, The issued Options were approved by issue of securities under dividend reinvestment plan, participation in Shareholders at the Annual General Meeting buy-back held on 16 November 2021 Part 2 - Change of director's interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part. Detail of contract Nil Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - + Closed period Were the interests in the securities or contracts detailed N/A above traded during a + closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Anatara Lifesciences Ltd